The aim of this study was to investigate the prognostic relevance of angiogenesis expressed as bone marrow microvessel density (MVD) in 40 patients with essential thrombocythemia (ET). Bone marrow MVD was visualized in paraffin tissue sections using immunohistochemical staining for CD34 protein. Increased MVD of bone marrow specimens was not significantly correlated with clinical (sex, age, microvascular disturbances, liver and spleen size, complications, treatment or no before biopsy), laboratory (peripheral blood count), bone marrow histopathological parameters (cellularity, megakaryocyte clumping and reticulin fibrosis) and overall survival. These preliminary findings suggest that angiogenesis has no prognostic value in patients with ET.

1.
Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653–660.
2.
Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.
3.
Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995;26:1757–1763.
4.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
5.
Bertolini F, Mancuso P, Gobbi A, Pruneri G: The thin red line: Angiogenesis in normal and malignant hematopoiesis. Exp Haematol 2000;28:99–100.
6.
Mangi M H: Review. Angiogenesis and angiogenic mediators in hematological malignancies. Br J Haematol 2000;111:43–51.
7.
Di Raimondo F, Palumbo GA, Molica S, Giustolisi R: Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 2001;106:177–183.
8.
Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398–1401.
9.
Aquayo A, Kantargian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, Freireich E, Albitar M: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240–2245.
10.
Mesa RA, Hanson CA, Rajkumar V, Schroeder G, Tefferi A: Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374–3380.
11.
Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J: Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15–19.
12.
Mesa RA, Hanson CA, Li C-Y, Yoon S-Y, Rajkumar SV, Schroeder G, Tefferi A: Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131–4137.
13.
Korkopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM, Terpos E, Stamatopoulos K, Plata E, Anargyrou K, Androulaki A, Davaris P,Yataganas X: Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: A morphometric study. Leukemia 2003;17:89–97.
14.
Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K: Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Haematol 2004;72:410–415.
15.
Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
16.
Harrison CN: Current trends in essential thrombocythaemia (review). Br J Haematol 2002;117:796–808.
17.
Schafer AI: Thrombocytosis (review). N Engl J Med 2004;350:1211–1219.
18.
Mesa R, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976–1995. Am J Hematol 1999;61:10–15.
19.
Murphy S, Peterson P, Iland H, Laszlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997;34:29–39.
20.
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY: Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474–2484.
21.
Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556–562.
22.
Harrison CN, Gale RE, Machin SJ, Linch DC: A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417–424.
23.
Panteli K, Christou L, Tsiara S, Kapsali E, Katsaraki A, Tzouvara E, Bourantas KL: A retrospective study on the clinical course of sixty-four patients with essential thrombocythaemia. Haema 2002;5:110–114.
24.
Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S: Practice guidelines for the therapy of essential thrombocythemia: A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215–232.
25.
Molica S, Santoro R, Iuliano F, Di Raimondo F, Fichera E, Giustolisi R: Serum levels of vascular endothelial growth factor in chronic leukemias: A comparative study with emphasis on myeloproliferative disorders. Haematologica 2001;86:771.
26.
Musolino C, Calabro L, Bellomo G, Martello F, Loteta B, Pezzano C, Rizzo V, Alonci A: Soluble angiogenic factors: Implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159–163.
27.
Lev PR, Marta RF, Vassallu P, Molinas FC: Variation of PDGF, TGFbeta, and b-FGF levels in essential thrombocythaemia patients treated with anagrelide. Am J Hematol 2002;70:85–91.
28.
Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabro L: Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol 2004;72:416–419.
29.
Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380.
30.
Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527–543.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.